Regulatory press release

THIS PRESS RELEASE IS AN ENGLISH TRANSLATION OF THE LEGALLY BINDING SWEDISH PRESS RELEASE: “PUBLICERING AV ÅRSREDOVISNINGEN FÖR 2CUREX AB (publ)”.

The Annual Report for 2025 for 2cureX AB (publ), 559128-0077, is now available.

The annual report, along with the auditor's report for 2cureX AB, as well as complete proposals for resolutions and proxy forms, can be accessed at the company's office at 2cureX, Fruebjergvej 3, 2100 Copenhagen, Denmark, and on the company's website (www.2curex.se).

Malmö, 28 May 2026

About 2cureX

2cureX is redefining cancer treatment selection through functional precision oncology. Its proprietary IndiTreat® test family creates thousands of 3D tumor replicas—called tumoroids—from a patient’s biopsy to identify which chemotherapy or targeted drugs that are most effective for that specific tumor. The result: real data to drive real decisions.
The first three IndiTreat® tests target patients with metastatic colorectal cancer:
• IndiTreat® Start (first-line therapy)
• IndiTreat® Extend & Explore (third-line options)

New IndiTreat® versions are in development for earlier-stage colorectal cancer and other GI cancers.
Despite global cancer IVD spending exceeding $17.5 billion annually, fewer than 1 in 3 treatments are guided by a predictive test. IndiTreat® aims to close that gap—bringing clarity to treatment selection and precision to every patient.

2cureX AB is listed on Nasdaq First North Growth Market under the ticker 2CUREX, with operational delivery in partnership with 2cureX A/S in Denmark. This cross-border structure powers the company’s new commercial strategy, Operation Twin Code—now live.